NanOlogy
  • Home
  • About
  • Technology
  • Development
    • Investigational Drugs
    • Pipeline
    • Clinical Trials
    • Partnering Opportunities
  • News & Publications
    • Recent News Highlights
    • Press Release Archives
    • NanOlogy In the News
    • Presentations & Publications Archive
  • Contact Us
    • Partnering Opportunities
    • Physicians and Patients
August 24, 2021 in Home Page, Publications

Medical Oncology: Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions

NanOlogy 1 Like Post Comments Off on Medical Oncology: Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions
Read More
NanOlogy

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.    Purcision is a trademark to CritiTech, Inc.  © NanOlogy LLC      Legal